Qiagen (QGEN) said Tuesday it plans to launch three new sample preparation instruments, QIAsymphony Connect, QIAsprint Connect, and QIAmini, between 2025 and 2026 to expand its automated sample preparation portfolio.
QIAsymphony Connect, expected to begin a phased launch in 2025, can process up to 96 samples per run and is designed for workflows including pathogen nucleic acid extraction, liquid biopsy, oncology, genomics, and clinical research. It features enhanced automation, digital connectivity, and integration with the QIAsphere cloud-based platform.
QIAsprint Connect, targeted for 2026, is aimed at high-throughput labs and has demonstrated the ability to process up to 192 samples per run with less than 30 minutes of hands-on time, supporting daily volumes of up to 600 samples. It accommodates a broad range of sample types, including plant, microbial, soil, stool, and human tissues.
Also slated for 2026, QIAmini is designed for low-throughput labs, offering a lower-cost entry point into automation with scalability for small batch workflows.
Shares of Qiagen were down 1.3% in recent trading.
Price: 41.78, Change: -0.55, Percent Change: -1.29
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.